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Matrix metalloproteinases (MMPs) – zinc containing endopep-
tidases which cleave the different components of the extracellu-
lar matrix. However, not all biological mechanisms and the
effects of these endopeptidases are well-established. Previously
it was believed that MMP functions only as proteolytic enzymes,
but it was found later that MMPs could act as regulators of protein
kinase signal transduction pathways by modifying receptors and
signaling molecules.
One of the most important substrates for MMP is transforming
growth factor-b (TGF-bÞ, which is a receptor for the ligand TGF-b-
signal transduction pathway comprises a network of protein
kinase pathways responsible for many of the processes of tumor
progression, including epithelial mesenchymal transformation
(EMT). Despite the fact that melanoma cells are not of epithelial
origin, they express the epithelial E-cadherin that is necessary
for their interaction with the basal layers of the epidermis. The
degradation of the extracellular matrix and loss of expression of
E-cadherin are major changes needed to start the processes of
melanoma invasion. One of the markers of EMT is a transcription
factor twist1. Twist1 activates the processes of epithelial-
mesenchymal transformation and increases the invasion of mel-
anoma cells by increasing transcription of MMP. The aim of this
study was to evaluate expression levels TGF-b, twist1 under selec-
tive inhibition of MMP-9 and combined inhibition of MMP-9 and-
13 in melanoma model in vivo; to determine the role of MMPs as
possible regulators of TGF-b-way signal transduction, as well as
associated with TGF-b EMT process.
The study was approved by the local Ethic Committee (proto-
col No. 144/ 2012 of 15.11.2012). Melanoma B16-bearing mice (con-
trol group consisted of 7 animals, MMP-9 inhibitor treatment
group – 7, MMP-9/13 inhibitor treatment group – 7 animals) under-
went experimental treatment by MMP inhibitor (Calbiochem,
USA) by daily application within 7 days. Control group consisted
of animals without treatment. Efficacy of MMP-9 inhibition was
evaluated by gelatinize zymography. TGF-b1 and twist 1 tran-
scription factor expression was determined by PCR real-time
using StepOne System (Applied Biosystems, USA). Statistical
analysis was done by Kruskal–Wallis test and Multiple Compar-
isons. The P values lower 0.05 were considered as significant.
It was found that the selective inhibition of MMP-9 did not
induce changes in expression levels of TGF-b and twist1, however,
the combined inhibition of MMP-9 and MMP-13 significantly
reduced the expression levels of the transcription factor twist1
and TGF-b. The results show that MMP-9 and MMP-13 act as acti-
vators of TGF-b-signal transduction pathway and could be consid-
ered as potential molecular targets for experimental therapy for
cancer.
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In 2004, COP1 was characterized as p53 E3-specific human
ubiquitin ligase according to in vitro studies. Later, oncogenic
activity of COP1 and correlation of its overexpression with level
of p53 protein in clinical tumor samples and cell lines were
shown. High expression level of COP1 was described in 25 of 32
cases of breast carcinomas and in 76 out of 171 cases of ovarian
carcinomas. High expression level of COP1 was described in hep-
atocellular carcinoma cell lines (PLC, Hep3B and HepG2, Huh7). In
40 of 55 cases of pancreatic cancer, overexpression of COP1 was
also noted. Some types of leukemia, melanoma, breast, lung
and prostate cancer contain focal deletions of COP1. COP1 overex-
pression was also found in non- oncological diseases like
Duchenne muscular dystrophy, ischemic cardiomyopathy and
juvenile dermatomyositis.
Similar to other p53-related E3 -ubiquitin ligases COP1 has dif-
ferent substrates. The selection of target for ubiquitination
depends on cell type or differentiation stage. Among the sub-
strates of COP1, besides p53 are: c-Jun, ETV1, ACC, TORC2, FOXO1
and C/EBPa, FIP200.
To identify novel proteins that interact with COP1 we applied
proteomics. Proteins co-immunoprecipitated with COP1 were
analyzed by MALDI -TOF mass spectrometry. To achieve this,
COP1–3xFlag expression vector was generated and transfected
into HEK 293T cells by calcium phosphate transfection method.
Protein complexes were immunoprecipitated with anti-FLAG
beads. Bound proteins were then separated by 1D SDS–PAGE gel
electrophoresis and analyzed by means of ESI-LC/MS/MS mass
spectrometry. Subsequent bioinformatics analysis of the interact-
ing proteins was employed. About 25% of identified proteins were
attributed to the cytoskeleton proteins, almost 20% of proteins
had known role in metabolism. According to the literature data,
it was not surprising to find several proteins involved in the lipid
metabolism. Finally, a significant groups of interactants play role
in transcription, cell adhesion, apoptosis, protein modification
and transport. It is important to note that several COP1-bound
proteins can be strong regulators of cell cycle in G2/M transition.
Our data can be used for the subsequent studies of previously
unknown roles of COP1 in different diseases.
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KRAS is component of Ras/MAPK signaling cascade that regu-
lates cell proliferation and cell survival. Somatic mutations in
KRAS gene are often found in tumors and affect the sensitivity
of tumors to target therapy. Mutations in codons 12 or 13 of KRAS
gene in colorectal cancer (CRC) are associated with resistance to
anti-EGFR antibodies Cetuximab and Panitumumab. The
objectives of this work were to develop PCR tests for detection
mutations in KRAS gene and analyze the frequency of mutations
in KRAS gene in CRC in Russia.
DNA sequencing by Sanger is the most common method for
mutation analysis. However, the method has a sensitivity of
20% mutant allele, which is often not sufficient for the analysis
of somatic mutations in tumors.
One of the most sensitive mutation analysis methods is allele-
specific real-time PCR. This method allows to detect 1% of
mutated DNA in the sample. This sensitivity is sufficient for anal-
ysis of mutations in tumor samples containing 2–5% or more of
tumor cells in normal tissue.
In this study we developed and compared 3 new KRAS assays
(1) real-time PCR with allele-specific primers; (2) real-time wild-
type blocking PCR with LNA (locked nucleic acid) blocker; and
(3) Sanger sequencing with LNA-blocker. First assay is a PCR test
with seven reactions using allele-specific primers for detection
and genotyping 7 mutations in 12 and 13 codons of KRAS gene.
Second assay is real-time PCR with only a single pair of primers
and LNA oligonucleotide blocker. LNA-blocker is an oligonu-
cleotide which has a wild-type sequence of codons 12 and 13
of KRAS gene. LNA-blocker binds strongly to wild-type KRAS
DNA and suppresses its amplification, but does not block ampli-
fication of mutant DNA. The real-time PCR with LNA -blocker
can detect mutant DNA but does not genotype mutation. Such
assay can be used as a simple and sensitive screening test for
mutant KRAS cases if exact genotyping of mutation is not
required. We also used LNA-blocker to increase sensitivity of
Sanger sequencing. To evaluate sensitivity and specificity of
new tests DNA standards were prepared with different ratios of
normal and mutant alleles using normal human DNA without
mutation and recombinant plasmids with mutations in KRAS
(G12C, G12S, G12R, G12V, G12D, G12A, G13D). After optimization
all three assays had sensitivity 5% of mutant alleles for the
detection of mutations in KRAS gene, using 2.5–40 ng of human
DNA.
Performance of new assays for KRAS mutations was compared
using 81 colorectal tumor samples. Before analysis relative con-
tent of tumor cells in the samples was evaluated by pathologist.
If tumor content was less than 20% in the sample then regions
with a maximum number of tumor cells were manually
macrodissected before the DNA extraction. DNA was purified
from formalin fixed paraffin embedded (FFPE) tissue using
‘‘FFPE-DNA Kit” (Biolink). All three assays had high sensitivity
(95–100%) and specificity (100%) for detection of KRAS mutations
in clinical tumor samples. Mutations of the KRAS gene were
found in 37 of 81 cases (46%) of CRC including 12 cases of muta-
tion G13D, 11 cases of G12D, 5 cases of mutation G12V, 4 cases
G12C, 3 cases of mutation G12A, 2 cases G12S, 1 case G13R. A sin-
gle case with mutation G13R wasmissed by allele-specific PCR but
was detected by real-time PCR with LNA-blocker and confirmed
by sequencing.
New assays have high sensitivity and specificity and are suit-
able for detection of KRAS mutations in clinical FFPE tumor
samples.
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Background: The analysis of circulating tumor nucleic acids
(DNAs and RNAs) in the blood seems to be a promising approach
for the development of the low-invasive methods of tumor detec-
tion, valuable for clinical practice. Detection of oncogenic and
tumor suppressor miRNAs in the blood plasma/serum is evidence
of their participation in pathogenesis and suggest the possibility
of their use as tumor markers and targets for therapy. Thus, the
determination of expression level of tumor-associated miRNAs
in plasma can lead to significant progress in understanding the
tumor development and treatment.
Aim: Estimation the changes in expression level of miRNAs
(miR-19b, miR-25, miR-125b, miR-126, miR-205) in blood plasma
from lung cancer patients during combined therapy and to
estimate their value as disease monitoring markers.
Materials and methods: Blood samples were taken from
patients (n = 23) with non-small cell lung cancer treated at the
Tomsk Cancer Research Institute. These samples were stabilized
and fractionated into plasma and blood cells. MicroRNA was iso-
lated from blood plasma using single-phase phenol-free extrac-
tion protocol and purified on silica-based spin columns
(BioSilica Ltd, Novosibirsk, Russia). Concentration of five above
mentioned miRNAs was measured by quantitative RT-PCR and
normalized to miR-16 using dCt method.
Results: In this study we analyzed the dynamic expression
changes of circulating DNA in blood plasma from lung cancer
patients during the combined therapy. Circulating miRNAs were
isolated from plasma samples of non-small cell lung cancer
patients before treatment, within 30 days after completing
chemotherapy and 15 days after surgery, by using developed
methodological approach. In case of miR-19b and miR-125b anal-
ysis was found that the miRNA expression level correlates with
clinical response to chemotherapy and surgery. Increasing level
of miR-19b and decreasing level of miR-125b were associated with
therapeutic response. Using Repeated measures ANOVA analysis
we demonstrated that the miR-19b and miR-125b expression
levels changes throughout three check-up points during the
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